Ra Pharmaceuticals (RARX) Begins Dosing of RA101495 in PNH Patients
Posted on
April 26, 2017 7:12 AM EDT
Initial Data from Global Phase 2 Program Expected Mid-2017
CAMBRIDGE, Mass.–(BUSINESS WIRE)– Ra Pharmaceuticals, Inc. (NASDAQ: RARX) today announced that it has initiated dosing in the Companys global Phase 2 clinical program evaluating RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Ra Pharma is a clinical stage biopharmaceutical company focusing on the development of next-generation therapeutics for the treatment of complement-mediated diseases and is developing RA101495 as a novel and potent subcutaneously-administered (SC) inhibitor of complement component 5 (C5). Inhibition of C5 is a clinically validated approach for the control…